<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063997</url>
  </required_header>
  <id_info>
    <org_study_id>CB102-21425</org_study_id>
    <nct_id>NCT02063997</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether arhalofenate is effective in preventing&#xD;
      flares and reducing serum uric acid in gout patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with sUA &lt; 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with sUA &lt; 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients experiencing at least one flare from baseline through Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients experiencing two or more flares from baseline through Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of flares from baseline through Week 4, from Week 5 through Week 8, and from Week 9 through Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of flares</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of flare treatment</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Flare composite score (summation of the daily maximum pain score on NRS during the duration of the flare)</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients experiencing flares who reached a sUA target &lt; 6 mg/dL during treatment</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of activity limitation associated with flare via HAQ-II</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in fractional excretion of urate</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in HbA1c and fasting TG in patients with HbA1c &gt; 7.0% and TG &gt; 150 mg/dL at baseline, respectively</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events (AE), and changes in vital signs and safety laboratory tests</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety-related study drug discontinuations</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Flare-related study drug discontinuations</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Steady-state arhalofenate acid serum and urine concentrations</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arhalofenate 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 300 mg; colchicine 0.6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate 600 mg</intervention_name>
    <description>Arhalofenate 600 mg tablets once daily for 12 weeks</description>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 mg</intervention_name>
    <description>Allopurinol 300 mg tablets once daily for 12 weeks</description>
    <arm_group_label>Allopurinol 300 mg</arm_group_label>
    <arm_group_label>Allopurinol 300 mg; colchicine 0.6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.6 mg</intervention_name>
    <description>Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks</description>
    <arm_group_label>Allopurinol 300 mg; colchicine 0.6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate 800 mg</intervention_name>
    <description>Arhalofenate 800 mg tablets once daily for 12 weeks</description>
    <arm_group_label>Arhalofenate 800 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 18 and 75 years of age, inclusive&#xD;
&#xD;
          -  Known gout diagnosis (per criteria of the American Rheumatism Association for the&#xD;
             classification of the acute arthritis of primary gout, see Appendix 3)&#xD;
&#xD;
          -  At least three patient-reported and documented flares during the 12 months prior to&#xD;
             screening (the first of these flares may have resulted in the gout diagnosis; any&#xD;
             recent flare must have resolved, with the patient back to usual comfort level at least&#xD;
             seven days prior to screening)&#xD;
&#xD;
          -  Have not used any ULT since at least two weeks prior to screening&#xD;
&#xD;
          -  Have not used colchicine since at least two weeks prior to screening&#xD;
&#xD;
          -  Usual level of resting pain when NOT experiencing flare is three or less on an&#xD;
             11-point numerical rating scale (NRS)&#xD;
&#xD;
          -  Have a sUA ≥ 7.5 mg/dL and ≤ 12 mg/dL at screening&#xD;
&#xD;
          -  All female patients must be surgically sterile or post-menopausal (at least 45 years&#xD;
             of age with no history of menses for at least two years); or have a partner who has&#xD;
             undergone vasectomy or must agree to use two medically accepted methods of&#xD;
             contraception including a barrier method (see Appendix 4) for the entire duration of&#xD;
             study participation unless she reports complete sexual abstinence. Female patients&#xD;
             must not be pregnant or lactating&#xD;
&#xD;
          -  Estimated creatinine clearance (eCrCl) ≥ 60 ml/min/1.73m2 calculated by&#xD;
             Cockcroft-Gault method at screening&#xD;
&#xD;
          -  Liver function tests ≤ 3X ULN for AST, ALT and total bilirubin; ≤ 3X ULN for ALP and&#xD;
             GGT; and ≤ 3X ULN for CK at screening&#xD;
&#xD;
          -  All other clinical laboratory parameters must be within normal limits or considered&#xD;
             not clinically significant&#xD;
&#xD;
          -  Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically&#xD;
             significant at screening&#xD;
&#xD;
          -  Systolic blood pressure ≤ 160 mm Hg and diastolic blood pressure ≤ 90 mm Hg at&#xD;
             screening; known hypertensive patients stable (blood pressure [BP] reading as above)&#xD;
             with medication may be included&#xD;
&#xD;
          -  Patients using agents known to influence sUA levels (see Appendix 7) must be on a&#xD;
             stable dose and regimen for at least two weeks prior to screening and must be willing&#xD;
             to continue the same doses and regimens during study participation&#xD;
&#xD;
          -  Expected to be able to tolerate a short course of either oral NSAIDs and/or oral&#xD;
             steroids as may be needed to treat a flare&#xD;
&#xD;
          -  Must be able to swallow tablets/capsules&#xD;
&#xD;
          -  Following training, must be willing and able to understand and complete an electronic&#xD;
             diary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving treatment with allopurinol, colchicine, probenecid, benzbromarone, or&#xD;
             febuxostat within two weeks or pegloticase within six months prior to screening&#xD;
&#xD;
          -  Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder or&#xD;
             organ transplant)&#xD;
&#xD;
          -  Diagnosis of xanthinuria&#xD;
&#xD;
          -  Fractional excretion of urate &gt; 10% at screening&#xD;
&#xD;
          -  History of documented or suspected kidney stones&#xD;
&#xD;
          -  Known infection with the human immunodeficiency virus (HIV) or history of viral&#xD;
             hepatitis type B or C&#xD;
&#xD;
          -  A diagnosis of illicit drug or alcohol dependence or abuse within one year of&#xD;
             screening&#xD;
&#xD;
          -  History of upper gastrointestinal (GI) bleeding, documented peptic ulcer disease&#xD;
             (unless known H. pylori infection treated successfully without recurrence), within&#xD;
             three years of screening&#xD;
&#xD;
          -  History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI),&#xD;
             congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention&#xD;
             procedure (including but not limited to angioplasty, stent placement, coronary&#xD;
             revascularization), lower extremity bypass procedure, systemic or intracoronary&#xD;
             fibrinolytic therapy within five years of screening&#xD;
&#xD;
          -  History of cancer within five years of screening, with the following exceptions:&#xD;
             adequately treated non-melanomatous skin cancers, non-metastatic prostate cancer or in&#xD;
             situ cervical cancer&#xD;
&#xD;
          -  Patients with a history of bladder cancer, active bladder cancer or hematuria&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 42 kg/m2 at screening&#xD;
&#xD;
          -  Current or expected requirement for anticoagulant therapy (except for aspirin ≤ 325&#xD;
             mg/day, clopidogrel [Plavix] ≤ 75 mg/day, or prasugrel [Effient] ≤ 10 mg/day)&#xD;
&#xD;
          -  Use of any of the following within eight weeks prior to screening: potent CYP3A4&#xD;
             inhibitors, cytotoxic agents (including azathioprine, mercaptopurine, cyclosporine,&#xD;
             cyclophosphamide, etc.), ranolazine, digoxin, theophylline, sulphonylureas,&#xD;
             thiazolidinediones (e.g., rosiglitazone or pioglitazone), atypical antipsychotic&#xD;
             agents, ampicillin, amoxicillin, loop diuretics or phenytoin&#xD;
&#xD;
          -  Chronic treatment with NSAIDs (except for as needed [prn] use to treat acute events);&#xD;
             per protocol a short course of oral NSAIDs may be used to treat flares during the&#xD;
             study&#xD;
&#xD;
          -  Current or expected chronic treatment with systemic corticosteroids (topical,&#xD;
             ophthalmic, intra-articular or inhaled corticosteroid at a dose &lt; 1600 μg/day is&#xD;
             permitted); per protocol a short course of oral corticosteroid may be used to treat&#xD;
             flares occurring during the study&#xD;
&#xD;
          -  History of intra-articular steroid injection to treat flare within four weeks of&#xD;
             screening&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to allopurinol or colchicine&#xD;
&#xD;
          -  Treatment with any other investigational therapy within 30 days or within five half&#xD;
             lives, whichever is longer, prior to screening&#xD;
&#xD;
          -  Patients who received arhalofenate in a previous trial&#xD;
&#xD;
          -  Any other condition(s) that would compromise the safety of the patient, prevent&#xD;
             compliance with the study protocol including ability to use an electronic diary, or&#xD;
             compromise the quality of the clinical study, as judged by the Investigator and/or&#xD;
             Medical Monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <disposition_first_submitted>February 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

